贺普丁联合单磷酸阿糖腺苷治疗慢性乙肝临床研究

目的:探讨慢性乙型肝炎病人接受贺普丁联合单磷酸阿糖腺苷的治疗效果。方法:178例慢性乙型肝炎病人随机分成治疗组和对照组,而治疗组用贺普丁联合单磷酸阿糖腺苷治疗2年;对照组单用贺普丁治疗2年。结果:贺普丁联合单磷酸阿糖腺苷治疗1年(12个月)后,HBV-DNA阴转率为47.3%,HBsAg血清阴转率20.4%;治疗2年(24个月)后HBV-DNA阴转率升至72.0%,HBsAg血清阴转率升至29.0%,ALT复常率为65.6%;明显高于对照组。结论:贺普丁联合单磷酸阿糖腺苷对治疗慢性乙型肝炎有明显疗效。

Clinical Research on Lamivudine Combined Vidarabini mono Phosphas to Treat Chronic Hepatitis B

Objective:To evaluate the effects from the chronic Hepatitis B patient treated by lamivudine combined vidarabini mono phosphas.Methods:one hundred and seventy eight patients suspicious of having chronic Hepatitis B randomly divided into therapy and contrrol groups,therapy group treated by lamivudine combined vidarabini mono phosphas for two years;contol group treated by lamivudine for two years.Results:after one year(12 months) treated by lamivudine combined vidarabini mono phosphas,47.3% of HBV-DNA appeared negative,20.4% of HBsAg serum appeared negative;after two years(24 months) treated,HBV-DNA appeared negative rising to 72.0%,HBsAg serum appeared negative rising to 29.0%,65.6% of alt healing;Obviously it much higher than control group.Conclusion:Lamivudine combined vidarabini mono phosphas had curative effects for treating chronic Hepatitis B.